Background Early treatment of coronavirus disease 2019 (COVID-19) with remdesivir in high-
risk patients, including those with immunosuppression of different causes, has not been …

Background Evidence remains inconclusive on any significant benefits of remdesivir in
patients with mild-to-moderate COVID-19. This study explored the disease progression …

Purpose Preliminary data suggest that remdesivir may influence the course of COVID-19
according to the duration of pre-admission symptoms. We aim to evaluate whether early use …

Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Objectives Remdesivir is one of the most widely recommended and used medications for
COVID-19 treatment. However, different outcomes have been reported for hospitalized …

Background Remdesivir treatment, like most antiviral drugs, is likely to be most effective
when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of SARS-CoV-2. Methods This was a retrospective comparative …

Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

Introduction: The evidence for remdesivir therapy in immunocompromised patients is scarce.
To evaluate remdesivir (RDV) effectiveness and safety in COVID-19 outpatients at high risk …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-
care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …